AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06765954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETBX-071 (PSA-based Oncolytic Virus)
Description: Administered subcutaneously (SC) before and after radiation therapy. The specific dosing schedule varies slightly depending on the cohort.
Study NCT06765954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M-CENK (Activated NK Cells)
Description: Administered intravenously (IV) before and after radiation therapy, also with variations in the timing and dosing across different cohorts.
Study NCT06765954 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiation Therapy (EBRT)
Description: This is a standard treatment administered to all participants. The specific dose and schedule (40 Gy in 5 fractions over 2 weeks or up to 9 weeks) are determined by the investigator based on clinical judgment.
Study NCT06765954 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Androgen Deprivation Therapy (ADT)
Description: May be used in conjunction with the other therapies. The specific type and duration of ADT are at the investigator's discretion, and it may be initiated up to 6 months after the completion of radiotherapy. This treatment is not part of the experimental treatment regimen.
Study NCT04796506 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Endurance Training (ET)
Description: Non-responders to PRT will transition too ET during 2nd 12 weeks of the study. This intervention is supervised endurance training, 3 times per week for 12 weeks. Each session lasts approximately 75 min., comprised of warm-up, stimulus phase for 50-60 min., and cool-down. Sessions are split between cycle ergometer and treadmill exercise. Participant heart rate is monitored to maintain target exercise intensity of 60-80% (±5%) of heart rate reserve (HRR).
Study NCT06765954 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Post-radiation immunotherapy
Description: The post-radiation immunotherapy phase in the ResQ110B-PROS study involves the continued administration of N-803, ETBX-071, and M-CENK, but with a specific schedule and after the completion of radiation therapy.
Study NCT02998229 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artisse™ Intrasaccular Device
Description: Intrasaccular Device
Study NCT05943106 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Participants will receive Durvalumab via intravenous infusion from Week 1 for 13 cycles every 4 weeks (q4w) for maximum 12 months.
Study NCT05943106 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG
Description: Participants will receive BCG via intravesical as induction weekly for 6 weeks starting at Week 1, Day 1 and subsequently for maintenance for 3 weekly doses up to 3, 6, 12, 18, and 24 months, at the physician's discretion as Standard of care.
Study NCT06653465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Acetaminophen, which has similarly effects with NSAIDs in terms of inhibition of cyclooxygenase COX1, COX2 and COX3, is widely used as adjuvant for perioperative multimodal analgesia.
Study NCT06653465 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline, a kind of crystalloid widely used in clinical treatment.
Study NCT05200572 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dyadic Life Review (DLR)
Description: DLR will consist of 8 sessions delivered by a trained licensed clinician (i.e, the PI or other trained clinician) via video-conferencing in weekly sessions of 60 minutes. Each session will facilitate a recall of each phase of life: childhood, adolescence, young adulthood, mid-life, earlier later life, and later life. While together, the patient and caregiver will each be asked structured questions to prompt reminiscence of memories from that phase of life.
Study NCT05335941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Given by vein (IV)
Study NCT05335941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimberelimab
Description: Given by vein (IV)
Study NCT05335941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrumadenant
Description: Given by PO
Study NCT05355792 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OmniTaper EV implants
Description: Partially edentulous subjects in need of one implant in the maxilla or mandible (2nd and 3rd molars excluded) will receive an OmniTaper EV implant system. The study will be done in accordance with standard dental practice using a one- or two-stage surgical protocol and immediate or delayed placement and/or loading.
Study NCT05279222 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gait adaptability training
Description: All patients will receive two gait training interventions, each consisting of twelve one hour training sessions. The training sessions will be focussed on improving gait capacity.
Study NCT05398380 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Liver transplantation
Description: Liver transplantation
Study NCT04854005 — intervention group
Intervention type: PROCEDURE
Intervention: Breast surgery
Description: Patients will undergo SLNB with single or dual-tracer lymphatic with technetium-99m sulfur colloid either lymphazurin or methylene blue dye, per institution standard, in accordance with routine clinical practice.
Study NCT04525547 — intervention group
Intervention type: DRUG
Intervention: Nintedanib
Description: Nintedanib
Study NCT06434402 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Intervention
Description: Write about cancer experiences
Study NCT05742009 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iCare ST500
Description: Measurement of Intraocular Pressure (IOP)
Study NCT05742009 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GAT
Description: Measurement of Intraocular Pressure (IOP)
Study NCT05742009 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iCare IC200
Description: Measurement of Intraocular Pressure (IOP)
Study NCT06662864 — intervention group
Intervention type: OTHER
Intervention: Patients reported outcomes
Description: Patients reported outcomes were collected via telephone
Study NCT06662864 — intervention group
Intervention type: OTHER
Intervention: questionnaire global Pittsburgh Sleep Quality Index (PSQI)
Description: Patients reported outcomes were collected via telephone
Study NCT04539457 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Desktop helper
Description: The 'Desktop Helper (version 10)' is a user-friendly information sheet developed by the IPCRG. This 'Desktop Helper (version 10)' has been developed in co-operation with several clinicians and experts in the field of COPD. These practical guidance and support are a tool for clinicians working in primary care. The 'Desktop Helper (version 10)' contains specific advice to prevent clashes. The specific advice of the 'Desktop Helper (version 10)' will be elaborated in decision trees. These will be integrated and implemented into the MedicomSmart system by Stichting Healthbase. Subsequently, these decision trees will provide GPs to conduct case-finding of COPD patients with 'medication-comorbidity clashes'. These are based on the 'Desktop Helper (version 10)' . Case finding will be done by the GP or the practice nurse (POH).
Study NCT04539457 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: E-learning
Description: The e-learning module will be explanatory to the 'Desktop Helper (version 10)' how to perform the case-finding and in what way the case-finding can be beneficial to the patients with COPD and their (co)morbidities. This e-learning module will include several example cases and how to deal with the case-finding and the next steps in the process to reduce the (co)morbidity clashes with the medications of COPD. Together with the decision trees as inferred from the 'Desktop Helper (version 10)', the e-learning module is aimed at inducing a behavioral change in prescribing medication to a patient suffering from COPD and one or more (co)morbidities.
Study NCT06508801 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood flow restriction training
Description: The BFR Intervention will consist of 75 repetitions; reps (set 1: 30 reps, sets 2 - 4: 15 reps with 30 s of rest between sets and 1 minute between exercises) at 20-30% of 10 repetition maximum (RM). BFR training will be performed during toe raises, lunges and single leg stance exercises on unstable surfaces (i.e., foam, Dyna disc, balance disc, and BOSU-ball®) as tolerated by the participant.
Study NCT06508801 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Instability Resistance Training
Description: The following devices will be used for instability training: foam, dyna disc, balance disc and BOSU-ball®. Unstable devices will be changed during the six-week period from the least to the most unstable devices. Once a participant reduces the body sway on a device, the device will be progressed. Participants will perform IRT with or without blood flow restriction.
Study NCT06508801 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Instability Resistance Training
Description: The following devices will be used for instability training: foam, dyna disc, balance disc and BOSU-ball®. Unstable devices will be changed during the six-week period from the least to the most unstable devices. Once a participant reduces the body sway on a device, the device will be progressed. Participants will perform IRT with or without blood flow restriction.
Study NCT05751031 — intervention group
Intervention type: DRUG
Intervention: Raltegravir
Description: Raltegravir exposure in pregnant women living with HIV in routine clinical care. No study intervention administrated.
Study NCT05492773 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Micro-osteoperforations Technique
Description: Micro-Osteoperforations Technique (MOPs) Surgery will be performed to the lower anterior bony segment of the lower jaw in order to accelerate tooth movement.
Study NCT05492773 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active comparater
Description: Active Comparator: Traditional treatment The patients in this group will be receive treatment with the traditional clear aligners technique without any surgical procedure.
Study NCT06235658 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gentle Yoga
Description: Participants will attend two virtual 60-minute gentle yoga sessions per week for 12 weeks. Each session will be conducted via videoconference using the Zoom platform, with participants joining from their homes.
Study NCT06233643 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phloroglucinol
Description: The active comparators will be treated with 40 mg of Phloroglucinol in the form of a single intramuscular injection.
Study NCT06233643 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Acupuncture Combined Intradermal Sterile Water
Description: Acupuncture was applied to a seated patient using the urinary bladder meridian points and combianed Intradermal Sterile Water in costovertebral area where the patient's pain was located (Sterile water of 0.5 ml was injected as intradermal into 4 points at a depth of 1-3 mm to form papules)
Study NCT04436458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niclosamide Oral Tablet
Description: Continued SOC therapy together with niclosamide TID for 14 days
Study NCT04436458 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Continued SOC therapy together with placebo tablets matching niclosamide for 14 days
Study NCT06365307 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Osteoplastic material based on octacalcium phosphate and biologically active nucleic acids for bone tissue regeneration Nucleostim-VEGF (Histograft)
Description: Due to the localization of the pathological process, all patients are divided into two groups: 1 - cervical spine, 2 - lumbar spine. Within these groups, patients are treated with either gene-activated osteoplastic material Histograft or synthetic osteoplastic material based on β-TCP (β-tricalcium phosphate) for spinal fusion of the cervical spine, or with bone autograft for spinal fusion of the lumbar spine.
Study NCT06365307 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Synthetic osteoplastic material based on β-TCP or bone autograft
Description: Due to the localization of the pathological process, all patients are divided into two groups: 1 - cervical spine, 2 - lumbar spine. Within these groups, patients are treated with either gene-activated osteoplastic material Histograft or synthetic osteoplastic material based on β-TCP (β-tricalcium phosphate) for spinal fusion of the cervical spine, or with bone autograft for spinal fusion of the lumbar spine.
Study NCT05974995 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robot-assisted surgery
Description: Total hysterectomy with bilateral salpingo-oophorectomy and lymphnodes staging using DaVinci Xi
Study NCT05974995 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic surgery
Description: Total hysterectomy with bilateral salpingo-oophorectomy and lymph nodes staging using standard laparoscopic approach
Study NCT04595682 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will attend two identical laboratory sessions to test sensitivity to the rewarding and disinhibiting effects of a controlled dose of alcohol, once during the early follicular phase and once during the late follicular phase. The test battery consists of measures of rewarding effects and alcohol (or placebo) effects on disinhibition and impulsive choice. The placebo consists of 300 ml of lemon-flavored soda with a small amount (3 ml) of alcohol floated on top.
Study NCT04595682 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alcohol
Description: Participants will attend two identical laboratory sessions to test sensitivity to the rewarding and disinhibiting effects of a controlled dose of alcohol, once during the early follicular phase and once during the late follicular phase. The test battery consists of measures of rewarding effects and alcohol effects on disinhibition and impulsive choice. The alcohol dose consists of 0.60 g/kg absolute alcohol that produces a peak blood-alcohol concentration of 80 mg/dl. Doses will be mixed with a carbonated, non-caffeinated, lemon-flavored soda and consumed within 10 minutes.
Study NCT06666166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A1811 & Apartinib
Description: SHR-A1811 injection will be administered by intravenous infusion. And apatinib will be administered orally.
Study NCT05561777 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physician-targeted CDS tool for PCN allergy delabeling
Description: This intervention will provide access to a best-practices alert (BPA) containing the patient's risk-stratification status and a link to the local standard of care protocol, oral amoxicillin challenge order set and written consent form (same resources as used in pharmacist -led electronic health record dashboard). If the provider opts to perform the oral challenge and it is successfully passed, a second BPA will prompt them to update the allergy status in the medical record.
Study NCT04942301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endostar
Description: This product combined with other combined chemotherapeutics is used to treat patients with stage III/IV NSCLC who are newly treated or relapsed
Study NCT04942301 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: use the vein pump to pump drugs
Description: During the first 14 days of the first cycle, the experimental drug was pumped daily with an intravenous pump. During cycles 2-4, subjects in group A were pumped with experimental drugs for 3 days and subjects in group B were pumped with experimental drugs for 7 days.
Study NCT04942301 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: combination therapy
Description: Combination therapy with chemotherapy drugs was used
Study NCT05781139 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: levels of Neurofilaments (NfL) in serum
Description: the levels Neurofilaments (NfL) (Abcam, USA), C-X-C motif chemokine 13 (CXCL13) and Chitinase 3-like Protein 1 (Sigma-aldrich, Germany) will be determined in the serum and CSF (if available) in the different participant groups.
Study NCT06666686 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active noise control headphone
Description: This is the group where active noise control headphones are applied. Headphones will be applied to patients from the beginning to the end of anesthesia induction.
Study NCT06666686 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Passive noise control headphone
Description: This is the group where passive noise control headphones are applied. Headphones will be applied to patients from the beginning to the end of anesthesia induction.
Study NCT06665750 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: A progressive upper extremity neuromuscular exercise program was performed face to face with the researcher physiotherapist for the study group. The exercise program was applied for approximately 20 minutes, 2 days a week for 6 weeks, on the same days of the week, before the participants' tennis training. The exercise content and number of repetitions in the training program changed every 2 weeks with increasing difficulty.
Study NCT05019833 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Signals collection
Description: A non-CE marked embedded software will be temporarily uploaded in the implanted device, in order to enable the collection of sensors signals.
Study NCT06129240 — intervention group
Intervention type: COMBINATION_PRODUCT
Intervention: LIQ861
Description: trepostinil inhalation powder
Study NCT06666010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEX010-Assisted Therapy
Description: The investigational medicinal product PEX010, containing 25 mg psilocybin, is a capsule for oral administration that contains the drug substance PYEX.
Study NCT06666010 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PEX010(01)
Description: The investigational medicinal product PEX010(01), containing 1 mg psilocybin, is a capsule for oral administration that contains the drug substance PYEX.
Study NCT06664866 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: EchoNet-LVH Assessment
Description: The AI algorithm is previously described (Duffy et al. JAMA Cardiology 2022) and will remain unchanged throughout the course of the study. A pre-determined threshold based on prior experiments and analysis has been decided prior to the study. From each site, approximately 100,000 echocardiogram studies will be reviewed by EchoNet-LVH for approximately 500 patients to be flagged.
Study NCT05326763 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Platelet Rich Plasma
Description: Preparing 2 mL of PRP with concentration of 4-6 times the average normal values, 20mL of blood will be first collected from the patient's upper limb cubital vein using an 18G needle. A local subcutaneous anesthesia (2 ml of 1% lidocaine) will be finished by the orthopedist.
Study NCT05326763 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dextrose 50%
Description: The group will use 4 ml of PRP + 4 ml of 0.9% saline -h 2 ml of 1% lidocaine (10-ml syringe).
Study NCT04865211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Description: Use of liposomal bupivicaine as intraoperative local anesthesia
Study NCT04865211 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Injection
Description: Use of bupivicaine as intraoperative local anesthesia
Study NCT04865211 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Use of saline as placebo for local anesthesia
Study NCT06666881 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIIT only
Description: After CCRT treatment 4-5 week, arrange participants do the HIIT exercise for two to three times a week and total 24-36 times.
Study NCT06666881 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIIT & Record of physical activities at home.
Description: After CCRT treatment 4-5 week, arrange participants do the HIIT exercise for two to three times in a week and total 24-36 times. And do the recording of physical activities at home.
Study NCT06666153 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EBV immunological agent
Description: 27 participants with will be enrolled in the study and divided into three groups, including EBV-LPD (Adults group), EBV-LPD (Children group) and PTLD (Adults group） each with 9 people.The participants will be divided into three different dose groups, and a 3+3 dose escalation design is used. The low dose is 5.0×10\^5, the medium dose is 2.0×10\^6 and the high dose is 5.0×10\^6 for children and low dose is 5.0×10\^6, the medium dose is 2.0×10\^7 and the high dose is 5.0×10\^7 for adults. Only one dose will be administered to each participant with EBV immunological agent combined with Toripalimab 240mg.
Study NCT06160739 — intervention group
Intervention type: DRUG
Intervention: Sirolimus 1Mg Oral Tablet
Description: patients with Microcystic , Mixed Lymphatic and Vascular Malformations will be given sirolimus 1 mg oral tab for 3-6 months with follow up of lesion size by clinical exam \& ultrasound \& MRI to compare lesion size before \& after use of the drug with observation of potential side effects \& after exclusion of it before use of the drug